Simon Sinclair appointed as chief medical officer of Ondine Biomedical

Appointments

Move of the month

Canadian life sciences company Ondine Biomedical has announced that it has appointed Dr Simon Sinclair as chief medical officer. This appointment comes as Ondine prepares to start its US phase 3 trial of its nasal photodisinfection technology.

Sinclair has over 20 years of pharma and medtech experience across translational medicine, clinical development, medical affairs, market access and medical safety and vigilance. He has worked as a non-executive director on Ondine’s board of directors since 2021.

Previously, Sinclair has held senior positions at a myriad of major pharma and medtech companies, including Johnson and Johnson Medical Devices and Merck and Co (MSD in the US).

Commenting on his appointment, Sinclair stated: "Having been closely involved with Ondine at board level, I am excited to join the company in an operational capacity at this critical stage, as we plan for entry into the US phase 3 trial and see growing interest and adoption in other key markets. […] Multidrug-resistant infections are an existential global healthcare threat, and there has never been a more important time to focus on new, non-antibiotic solutions. I look forward to working with the Ondine team to bring its photodisinfection technology through the FDA regulatory process in the US and continuing to build usage and implementation across the countries where we already have approval, including Canada, EU and UK."

Alfonso Quintás-Cardama to join Foghorn Therapeutics as new chief medical officer

The biotechnology company foghorn therapeutics has announced the addition of the new chief medical officer, Alfonso Quintás-Cardama, who will be replacing Sam Agresta after his retirement on 11 September 2023.

Helmholtz Centre for Infection Research appoints Josef Penninger to new scientific director

The Helmholtz Centre for Infection Research (HZI), Germany, has appointed professor Josef Penninger as scientific director.

Olav Hellebø to join Cytovation’s board of directors

Cytovation, a clinical stage immune-oncology company with a focus on targeted tumour membrane immunotherapies, has announced that it has appointed Olav Hellebø to its board of directors.

Reacta appoints Kevin Hawkins as new head of regulatory affairs

Immodulon appoints Josefine Roemmler-Zehrer as chief medical officer

Immodulon, a late-stage clinical company developing highly differentiated cancer immunotherapies to prime a patient’s own immune system, has announced that it has appointed Dr Josefine Roemmler-Zehrer as chief medical officer.

Alfonso Quintás-Cardama to join Foghorn Therapeutics as new chief medical officer

Helmholtz Centre for Infection Research appoints Josef Penninger to new scientific director

Olav Hellebø to join Cytovation’s board of directors

Reacta appoints Kevin Hawkins as new head of regulatory affairs

Immodulon appoints Josefine Roemmler-Zehrer as chief medical officer

Pharmafocus

Categories

Social Footprints